Skip to main content

Advertisement

Log in

PET and restaging of malignant lymphoma including residual masses and relapse

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Differentiation of post-therapeutic scar tissue from active lymphoma is unsatisfactory when using only morphological imaging approaches. Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) may provide superior clinical information by enabling biochemical tissue characterisation, with enhanced FDG uptake in viable post-therapeutic lymphoma masses and very low uptake in indolent fibrotic tissue. With this in mind, 15 recently published studies reporting the results of differentiation of viable lymphoma from scar tissue in 723 patients were analysed. Sensitivity of FDG-PET for detection of active disease was 71–100%, and the specificity was 69–100%. Accordingly, FDG-PET had a high negative predictive value of 80–100%. In contrast, the specificity and positive predictive value (PPV) of computed tomography were low (4–31% and 19–60%, respectively, except in one study in which the PPV was 82%). Residual masses that were positive on PET were associated with a progression-free survival of 0–40%. Although not perfect, the biochemical approach for characterisation of residual masses in lymphoma with FDG-PET at present seems the most accurate way to differentiate scar tissue from viable residual lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2a, b.
Fig

Similar content being viewed by others

References

  1. Dalla-Favera R, Gaidano GL. Lymphomas. In: De Vita VT, Rontrey SA, eds. Cancer, principles of oncology. Philadelphia: Lippincott Williams and Wilkins; 2001:2215–2387.

  2. Aisenberg A. Problems in Hodgkin's disease management. Blood 1999; 93:761–779.

    CAS  PubMed  Google Scholar 

  3. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer 2002; 38:1167–1172.

    Article  CAS  PubMed  Google Scholar 

  4. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931–933.

    CAS  PubMed  Google Scholar 

  5. Lowe V, Wiseman GA. Assessment of lymphoma therapy using18F-FDG PET. J Nucl Med 2002; 43:1028–1030.

    Google Scholar 

  6. Hoskin P. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29:449–451.

    Google Scholar 

  7. Segall G. FDG PET imaging in patients with lymphoma: a clinical perspective. J Nucl Med 2001; 42:609–610.

    Google Scholar 

  8. DeWit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld D. Whole-body PET for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8:57–60.

    Article  Google Scholar 

  9. Cremerius U, Fabry U, Neuerburg J, Zinmy, Osieka R, Buell U. Positron emission tomography with18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055–1063.

    CAS  PubMed  Google Scholar 

  10. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999; 38:799–804.

    CAS  PubMed  Google Scholar 

  11. Bangerter M, Moog F, Griesshammer M, et al. Role of whole-body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment. Radiography 1999; 5:155–163.

    Google Scholar 

  12. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91:302–310.

    Article  CAS  PubMed  Google Scholar 

  13. Cremerius U, Fabry U, Kroll U, et al. Klinische Wertigkeit der FDG-PET zur Therapiekontrolle bei malignen Lymphomen—Ergebnisse einer retrospektiven Studie an 72 Patienten. Nuklearmedizin 1999; 38:24–30.

    CAS  PubMed  Google Scholar 

  14. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429–433.

    CAS  PubMed  Google Scholar 

  15. Maisey N, Hill M, Webb A, et al. Are18fluordeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 26:200–206.

    Article  Google Scholar 

  16. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613–618.

    CAS  PubMed  Google Scholar 

  17. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with (18F)-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 15:272–278.

    Article  Google Scholar 

  18. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–419.

    CAS  PubMed  Google Scholar 

  19. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793–800.

    Article  CAS  PubMed  Google Scholar 

  20. Weihrauch M, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using F-18-FDG for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930–2934.

    CAS  PubMed  Google Scholar 

  21. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with (18F)2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16:260–267.

    Article  CAS  PubMed  Google Scholar 

  22. De Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld D.18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12:29–37.

    PubMed  Google Scholar 

  23. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27:731–743.

    Article  CAS  PubMed  Google Scholar 

  24. Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske S. Vortäuschung eines mediastinalen Non-Hodkin-Lymphomrezidivs durch diffuse Thymushyperplasie im18F-FDG-PET. Fortschr Röntgenstr 1996; 165:309–310.

    Google Scholar 

  25. Spaepen K, Mortelmans L. Evaluation of treatment response in patients with lymphoma using (18F)FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Q J Nucl Med 2001; 45:269–273.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. N. Reske.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reske, S.N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S89–S96 (2003). https://doi.org/10.1007/s00259-003-1167-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1167-4

Keywords

Navigation